Desjardins upgraded DexCom, Inc. (NASDAQ:DXCM) to Buy in a report released today.
- Updated: September 16, 2016
Only yesterday DexCom, Inc. (NASDAQ:DXCM) traded 1.18% higher at $92.24. The company’s 50-day moving average is $91.68 and its 200-day moving average is $75.01. The last stock price close is up 25.11% relative to the two hundred day average, compared to the S&P 500 Index which has decreased -0.01% over the same time. 81,862 shares of DXCM were exchanged, down from ann average volume of 840,834.
Desjardins has upgraded DexCom, Inc.(NASDAQ:DXCM) to Buy in a statement released 9/16/2016.
DexCom, Inc. has a 52 week low of $47.92 and a one-year high of $102.67. DexCom, Inc.’s market capitalization is currently $0.0.
General Information About DexCom, Inc. (NASDAQ:DXCM)
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. It had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, and enabling commercialization of the DexCom G4 system. DexCom SHARE enables users of its G4 PLATINUM System to have their sensor glucose information remotely monitored by their family or friends. The G4 PLATINUM Receiver with Share uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient’s receiver and a mobile application on the patient’s iPhone to transmit glucose information.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.